Convergent Therapeutics
Investors
Venture capital firms, private equity investors, and strategic partners
| Investor | Type |
|---|---|
RA Capital Management | Venture Capital |
Novo Holdings | Other |
OrbiMed | Growth Equity |
The Invus Group | Pe Buyout |
Common Investor Types
- •Venture Capital Firms: Early-stage and growth equity investors
- •Private Equity: Later-stage institutional investors
- •Strategic Investors: Corporations in related industries
- •Angel Investors: High-net-worth individuals
- •Family Offices: Private wealth management firms
What Investors Provide
- ✓Capital for growth and expansion
- ✓Strategic guidance and expertise
- ✓Industry connections and partnerships
- ✓Market validation and credibility
- ✓Board representation and governance
Who Invested in Convergent Therapeutics?
Convergent Therapeutics has attracted investment from 4+ venture capital firms, private equity investors, and strategic partners across 1 funding rounds. These investors have provided a total of $130M in capital to fuel the company's growth in the Drug Discovery sector.
Why Do Investors Fund Convergent Therapeutics?
Investors are attracted to Convergent Therapeutics due to the company's strong market position, growth potential, and proven business model in the Drug Discovery industry. The company's current valuation of $280M reflects investor confidence in its ability to generate returns through continued growth, potential IPO, or strategic acquisition.
Types of Convergent Therapeutics Investors
Convergent Therapeutics investors typically include a mix of venture capital firms providing growth capital, private equity firms for later-stage funding, strategic corporate investors from related industries, and high-net-worth angel investors. Each investor type brings unique value beyond capital, including industry expertise, strategic partnerships, and operational guidance.
Investor FAQs
How many investors does Convergent Therapeutics have?
Convergent Therapeutics has had 4+ investors participate across its funding rounds. This includes venture capital firms, private equity investors, strategic partners, and angel investors.
Who are the lead investors in Convergent Therapeutics?
Lead investors typically invest the largest amounts and often take board seats. For detailed information about Convergent Therapeutics's lead investors and cap table structure, please contact our team.
Can I become an investor in Convergent Therapeutics?
Accredited investors can purchase Convergent Therapeutics shares on the secondary market through Premier Alternatives. This provides an opportunity to invest in the company before a potential IPO or acquisition event.